Dr. Vivian Cintron’s Post

👩⚕️ One of the biggest challenges in oncology is resistance. 1 in 2 people will be diagnosed with cancer in their lifetime, and over 90 % of cancer deaths are caused by drug resistance, one of the biggest unmet medical needs in the field of cancer. 👨⚕️   🎯 At Heidelberg Pharma AG the patient is the focus of all our efforts! Our amanitin-based ADC pipeline is designed to overcome resistance. 🎯 📌 Learn more about our patient-focused approach by watching our R&D webinar: https://lnkd.in/eVJygzyn   #ADCs #ATAC #CancerResearch

New FDA-Approved Targeted Drug for Treatment-Resistant, Estrogen (ER) Positive HER2 Negative Breast Cancer Precision Oncology specialist, Alex Rolland, discusses a new recently FDA-approved targeted treatment for patients with treatment-resistant ER positive HER2 negative breast cancer. Watch this video to learn 👇 ✅What new treatment has recently been approved ✅Exploring the results of the CAPItello-291 trial ✅How these results led to the treatment being FDA-approved ✅Who this treatment will work for ✅Explanation of statistics used in this trial ✅What tests a patient needs to determine if this treatment will work for them ✅Next steps patients can take to access this treatment Alex is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share key takeaways about this new treatment, including how to access it through a patient's current treatment team. Click to watch 👉https://buff.ly/3TSsP3I 👀 #HopeIsHere #PrecisionCancerMedicine

Imfinzi Granted Priority Review for MIBC!💉 IMFINZI® (durvalumab) HCP takes a critical step forward as the FDA grants it Priority Review for treating muscle-invasive bladder cancer (MIBC). 🧬 This recognition underscores its potential to transform cancer care and improve patient outcomes.🚀 AstraZeneca Murali Reddy, Prashant Sharma, Parag Mahajan Know complete story - https://lnkd.in/gzEKvtZT #Imfinzi #PriorityReview #MIBC #CancerCare #MedicalBreakthrough

New FDA-Approved Targeted Drug for Treatment-Resistant, Estrogen (ER) Positive HER2 Negative Breast Cancer Precision Oncology specialist, Alex Rolland, discusses a new recently FDA-approved targeted treatment for patients with treatment-resistant ER positive HER2 negative breast cancer. Watch this video to learn 👇 ✅What new treatment has recently been approved ✅Exploring the results of the CAPItello-291 trial ✅How these results led to the treatment being FDA-approved ✅Who this treatment will work for ✅Explanation of statistics used in this trial ✅What tests a patient needs to determine if this treatment will work for them ✅Next steps patients can take to access this treatment Alex is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share key takeaways about this new treatment, including how to access it through a patient's current treatment team. Click to watch 👉https://buff.ly/3TSsP3I 👀 #HopeIsHere #PrecisionCancerMedicine

New FDA-Approved Targeted Drug for Treatment-Resistant, Estrogen (ER) Positive HER2 Negative Breast Cancer Precision Oncology specialist, Alex Rolland, discusses a new recently FDA-approved targeted treatment for patients with treatment-resistant ER positive HER2 negative breast cancer. Watch this video to learn ✅ What new treatment has recently been approved ✅ Exploring the results of the CAPItello-291 trial ✅ How these results led to the treatment being FDA-approved ✅ Who this treatment will work for ✅ Explanation of statistics used in this trial ✅ What tests a patient needs to determine if this treatment will work for them ✅ Next steps patients can take to access this treatment Alex is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share key takeaways about this new treatment, including how to access it through a patient's current treatment team. Click to watch 👉https://buff.ly/3TSsP3I 👀 #HopeIsHere #PrecisionCancerMedicine

The FDA has approved durvalumab (Imfinzi) for limited-stage small cell lung cancer, a significant step forward for oncology care. At CSI, we understand the urgency of sourcing breakthrough comparators into clinical trials. If your study requires Imfinzi, our team can efficiently source it to keep your trials moving forward. With expertise in global studies and a commitment to reducing lead times, we’re here to support your trial success. #OncologyComparators #ClinicalTrials #Imfinzi #FullSupplyChainSolutions

New FDA-Approved Targeted Drug 🩺 for Treatment-Resistant, Estrogen (ER) Positive HER2 Negative Breast Cancer 💗 Precision Oncology specialist, Alex Rolland, discusses a new recently FDA-approved targeted treatment for patients with treatment-resistant ER positive HER2 negative breast cancer. Watch this video to learn 👇 ✅ What new treatment has recently been approved ✅ Exploring the results of the CAPItello-291 trial ✅ How these results led to the treatment being FDA-approved ✅ Who this treatment will work for ✅ Explanation of statistics used in this trial ✅ What tests a patient needs to determine if this treatment will work for them ✅ Next steps patients can take to access this treatment Alex is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share key takeaways about this new treatment, including how to access it through a patient's current treatment team. Click to watch 👉https://buff.ly/3TSsP3I 👀 #HopeIsHere #PrecisionCancerMedicine

New FDA-Approved Targeted Drug for Treatment-Resistant, Estrogen (ER) Positive HER2 Negative Breast Cancer Precision Oncology specialist, Alex Rolland, discusses a new recently FDA-approved targeted treatment for patients with treatment-resistant ER positive HER2 negative breast cancer. Watch this video to learn ✅ What new treatment has recently been approved ✅ Exploring the results of the CAPItello-291 trial ✅ How these results led to the treatment being FDA-approved ✅ Who this treatment will work for ✅ Explanation of statistics used in this trial ✅ What tests a patient needs to determine if this treatment will work for them ✅ Next steps patients can take to access this treatment Alex is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share key takeaways about this new treatment, including how to access it through a patient's current treatment team. Click to watch 👉https://buff.ly/3TSsP3I 👀 #HopeIsHere #PrecisionCancerMedicine

Working on blood cancer drug development? We have a comprehensive and well-characterized panel of hematological PDX models. Let’s identify the models suitable to your objectives: subcutaneous, orthotopic, or disseminated growing, adapted to your modality and mode of action and target. Start a discussion with our expert. https://okt.to/KicI1M 

Adjuvant therapy using nanotechnology-based formulations for non-small cell lung cancer (NSCLC) offers a promising next step in treatment by enhancing the delivery of drugs directly to cancer cells while minimizing side effects. Nanoparticles can encapsulate chemotherapeutic agents, targeting tumor cells more precisely through mechanisms like passive targeting (enhanced permeability and retention) or active targeting (ligand-receptor interactions). This allows for improved drug bioavailability, reduced toxicity to healthy tissues, and overcoming drug resistance. Nanotechnology also supports personalized medicine by tailoring drug delivery systems to individual tumor characteristics, which could significantly improve patient outcomes and long-term survival. #JNJOncology #Nanocarriers #Lungcancer #Chemotherapy #Pulmonaryroute #NASLC #Aerosol